MAM
Mudra Max creates Slice Mango lounges
MUMBAI: Mudra Max has launched an on-the-ground promotional activation for Slice, PepsiCo’s mango drink. Slice Mango lounges aims to reach out over 1.5 million consumers by the end of the campaign in June 2011.
The agency has stationed Mobile–Slice Mango lounges at multiple locations in various cities across India. According to Mudra, the key task is to make the target audience taste mango packaged in the form of Slice.
The Slice Mango lounges have been created out of four buses, where the visitors are served Slice based mocktails.
Mudra Max Celsius SVP Sanjay Kacker said, “Bringing the product to life’ was the objective and we were successful in doing so, thus allowing the end consumers to actually sense & feel the brand closely. This innovative use of consumer sampling will not only give the consumer a taste but will also help drive consumption via repeat purchase.”
PepsiCo India director juices and juice drink Homi Battiwala adds, “Experiential sampling in small towns is a big priority for brand Slice this year, and the Slice Mango Lounge activation conceptualised by Mudra Max does a great job of driving this priority. The lounge has been on road for over six weeks now and we are delighted with the consumer traction and response. Look forward to Mudra continuing with their expertise in innovative activations with efficient operations and consumer insights. Keep it up team Mudra.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
